therapeutic active substance, when intended for the treatment of primary dysmenorrhoea where the
maximum daily dose is 500 milligrams 3 times a day and the maximum treatment period is 3 days. (S3)
Mepenzolate bromide.
Mephenesin.
Mercuric ammonium chloride.
Mercuric chloride.
Mercuric iodide.
Mercuric oxides; substances, preparations and mixtures thereof, except those containing less than 3 per
cent of mercury.
Mercury organic compounds; substances, preparations and mixtures in the form of aerosols, intended
for application to the skin and mucous membranes and substances, preparations and mixtures
containing the equivalent of 0,6 per cent or more of elemental mercury, intended for application to the
skin and mucous membranes, except phenylmercuric nitrate when registered in terms of the provisions
of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of
1947).
Mesna, except preparations intended for injection. (S4)
Metaproterenol (orciprenaline) except when contained in respirator solutions (S3) and except when
intended for injection or for the prevention or delay of labour. (S4)
Methixene
Methocarbamol, when intended for medicinal purposes.
Methoxyphenamine.
Miconazole, when intended for human use in preparations containing 2 percent or less of miconazole,
for the topical treatment of fungal infections of the mouth (oral candidiasis). (S1, S4)
Minoxidil, when intended for application to the scalp. (S4)
Morphine; mixtures containing 0,2 percent or less of morphine, calculated as anhydrous morphine. (S6)
Nabumetone, when intended for the treatment of post-traumatic conditions such as pain, swelling and
inflammation, for a maximum period of 5 days. (S3)
Naproxen,
(a)
as the sodium salt, when intended for the short term management of headache,
toothache, muscular ache, backache, minor pain associated with arthritis, pain associated with
menstrual cramps (dysmenorrhoea), minor aches and pains associated with the common cold and
fever, at a maximum dose of 600 milligrams naproxen (660 milligrams naproxen sodium) in 24 hours;
(b)
and when supplied by a pharmacist to a patient and intended for the emergency
treatment of acute gout attacks or for the treatment of post traumatic conditions such as pain, swelling
and inflammation, for a maximum period of 5 days. (S1, S3)
Nedocromil.
Nicergoline.
Nicotine when intended for human medicinal use, except—
(a)
nicotine gum containing 4mg or less nicotine per piece where the pack size does not
exceed 30 pieces per pack when these medicines are used for the relief of nicotine withdrawal
symptoms as an aid to smoking cessation only (S0).
(b)
nicotine transdermal patches for continuous application to the skin in strengths up to
and including 15mg/16 hours when these medicines are used for the relief of nicotine withdrawal
symptoms as an aid to smoking cessation only. (S1)
Nizatidine, when administered orally for short-term symptomatic relief of heartburn and hyperacidity,
subject to—
(a)
a maximum dose of 150 milligrams;
(b)
a daily dose of 300 milligrams;
(c)
a maximum treatment period of two weeks. (S4)
Norcodeine; preparations and mixtures when compounded with one or more therapeutically active
substances and containing 20 milligrams or less of norcodeine (calculated as base) per dosage unit and
liquid oral preparations and mixtures containing 20 milligrams or less of norcodeine (calculated as base)
per 5 millilitre dosage unit. (S6)
Noscapine.
Nux vomica; substances, preparations and mixtures thereof, except when registered in terms of the
provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Octatropine methylbromide.
Oleoresin of aspidium (Filix Mas).
Olopatadine.
Opium; mixtures containing not more than 0,2 percent of morphine, calculated as anhydrous morphine.
(S6)
Orphenadrine.
Otilonium bromide.
Oxybuprocaine, when contained in eye drops intended for emergency treatment of arc eyes. (S4)
Oxyphencyclimine.
Oxyphenonium.
Papaverine; substances, preparations and mixtures thereof.